ArticleBMJ open2016
Research funding for addressing tobacco-related disease: an analysis of UK investment between 2008 and 2012.
Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionTobacco use is the leading cause of preventable death in the UK. However, research spending on tobacco-related disease, and particularly smoking prevention, is thought to be low. We therefore aimed to assess the relation between tobacco-related research investment and disease burden from 2008 to 2012.
methodsWe used the Health Research Classification System to classify UK government and charitable research funding by broad health category and then by tobacco prevention research and 18 WHO defined tobacco-related diseases. We used UK mortality figures to calculate disease-specific tobacco attributable deaths and then compared disease specific and tobacco prevention research investment with all cause and tobacco attributable mortality over the 5-year period and as annual averages.
results12 922 research grants were identified with a total value of £6.69bn, an annual average of £1.34bn. Annually an average of 110 000 people die from tobacco-related disease, approximately 20% of total deaths. £130m is invested in researching tobacco-related disease each year and £5m on tobacco prevention, 10.8% and 0.42% of total annual research funding, respectively. Prevention research equated to an annual average of £46 per tobacco attributable death or one pound for every £29 spent on tobacco-related disease. Funding varied widely for diseases with different numbers of deaths (eg, lung cancer £68 per all cause death, cervical cancer £2500), similar numbers of deaths (leukaemia £983 per death, stomach cancer £43) or similar numbers of tobacco attributable deaths (eg, colorectal cancer £5k, pancreatic cancer £670, bladder cancer £340).
conclusionsTobacco-related research funding is not related to burden of disease or level of risk. As a result certain diseases receive a disproportionately low level of research funding and disease prevention funding is even lower.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.